In 1923,Frank Silver and Irving Cohn publisheda song that became a major hitfor the Billy Jones Orchestra, with thesignature line Yes, we have no bananas; we have no bananas today. It turned out to be sadly prophetic as, in the 1950s, the banana trees that supplied the entire global banana export business were wiped out by a soil-borne fungal diseaseknown asPanama Wilt.
The industry at that time was almost entirely based on a single banana cultivar called Gros Michel (meaning Big Mike), and it was susceptible to infection by a strain of fungus called Fusarium. Once the soil of a given plantation was contaminated with that strain, any Gros Michel tree grown there would soon die.
By good fortune, a different banana cultivar that was being grown in the South Seas was able to substitute for Gros Michel as a commercial line, and this new Cavendish cultivar became the new banana of international commerce, as it remains to this day. (Check out this interesting blog post about the history of the Cavendish variety and how it actually passed through a greenhouse in England in that process! And here is another good post about the history of this disease and the industry.)
Unfortunately, its about time for some band to cover Yes, We Have No Bananas because, evolution being what it is, a new strain of Fusarium Tropical Race 4 has arisen and it is lethal to the Cavendish. The disease is slowly making its way around the world, and since it can be spread in a particle of dirt on something like a boot, it will almost inevitably make it to the Central and South American growing regions that supply both North America and Europe with their bananas.
Although this unfortunate scenario has been on the minds of the banana industry for decades, it is now starting to get more attention in the mainstream press. One part of the story that has been shocking to these outside observers is that such a huge industry would ever be dependent on a single cultivar of banana. As Stephen Mihm put it for Bloomberg, this looming bananapocalypse is attributable to a vulnerability that comes from the practice of extreme monoculture.
While I understand why observers might be shocked that a nearly $12 billion industry depends almost exclusively on the Cavendish banana, I do want to push back on the implied conclusion that this represents some sort of irrational or irresponsible expression of big ag or whatever other demons are imagined by the Food Movement.
When you see something that is a standard practice in a very large, nationally diverse and multi-company business like bananas, I would suggest that it is appropriate to ask not what is wrong with this system but rather, What are the practical factors that drive this seemingly irrational practice?
Im not a banana expert, but in the mid-1990s, two of my first jobs as an independent consultant had to do with the banana industry. It was during the exciting early years of commercial plant biotechnology, and many industries were asking, What might this new technology do for our business? Both of my projects involved early-stage discussions between a major banana company and a plant biotech company four different entities in all. These were drawing board stage projects, with the goal of figuring out if certain ideas could ever make economic sense: Would they be something worth years of effort and millions of dollars for research?Still, overall, biotechnology looked like a way for this industry to tap into genetic diversity.
The fun part for me was getting to do a deep dive into the details of how bananas are grown, handled, shipped and marketed. I got to travel to Honduras, Costa Rica and Ecuador to tour banana plantations and interact with experts at the major banana export companies. As I said, Im not an industry insider, but I think I can shed some light on why there are not more kinds of bananas grown for export.
As modern consumers, we are offered an amazingly diverse selection of fresh fruits and vegetables year-round, so it is important to think back to the early days of this offer of plenty. Having grownup in Denver in the 1960s, I can recall that, except for a few summer months, almost the only fresh fruit options at the grocery store were bananas, apples and oranges. I have a podcast aboutwhy apples were ever on that list. But if you think about it, the very fact that we can so easily enjoy fresh bananas in temperate regionsis a bit remarkable.
Bananas can grow only in regions where there is never frost, and they do best in truly tropical climates. How did a tropical fruit become a mainstream, reasonably priced, healthful, kid-popular fruit for people who experience winter?
In tropical regions, there is a great deal of genetic diversity among wild bananas and considerable diversity among the banana or plantain types that humans cultivate. However, very few of these bananas could ever meet the criteria needed to be a viable export crop.
First of all, a banana for export has to be seedless. Many wild bananas have large, very hard black seeds not something that has much consumer appeal. The bananas that people like are seedless because they have triploid genetics three of each chromosome vs. the two that we have. That is the same way we get seedless watermelons, grapes, etc. Its not some GMO thing; it happens at times in the plant kingdom, and we humans like it! Still, improving or changing the cultivar through conventional breeding isnt an option if it makes no seeds.
Next, the banana needs to be productive in terms of overall yield per tree or acre. Im sure no one in the 1920s was calculating it, but in modern sustainability thinking, the land-use efficiency of a crop is an important criterion. That, along with water-use efficiency, small carbon footprint and energy footprint,is all very much tied to good yield. The usable per-hectare yields of the Cavendish variety are quite high, and that is why it has been a both economically viable and environmentally sustainable choice for a long time.
But probably the most limiting requirement for a banana variety to be commercially acceptable is thatit has to be shippable. In the modern era, we have lots of transport options for food products, but during the era when the banana was becoming an item of international trade, the only viable option was ocean shipping. A product being moved from the tropics to North America or Europe needed a very-low-cost transport option if it was ever going to be a mainstream consumer product. Most fresh produce products loaded onto a ship for a two-plus-week trip to a northern port would be a soup of decay by the time they arrived.
What made the Gros Michel and its successor, the Cavendish, remarkable was that they could make that trip at a temperature range of 55-58 degrees Fahrenheit, and so not even require lots of energy for refrigeration. Very few of the wonderful range of cultivated or wild banana types could ever do that, but because the Cavendish can be shipped this way, the energy and carbon footprint ofits shipment is small. This crop has a very attractive food-miles profile.
In addition,it turns out that the conditions under which bananas grow can affect their shipping potential. There is a disease that infects only the leaves of banana plants called Black Sigatoka. If a banana tree has suffered too much of that infection, even the robust Cavendish variety wont be able to make the trip by sea. One thing I learned on my tour was that plantations have employees whose whole job is to survey the plantation on a tree-by-tree basis in order to qualify the fruit for shipment based on how well that disease has been managed.
But it gets even more complicated than that (heres a good video summary of the process). Bananas are picked in Central and South America at a green stage imagine a fruit more completely green than the greenest one youve ever seen in the clusters in your store. When they get to their destination, they are put into ripening rooms, where they are exposed to ethylene gas to start them on the way to the ripe yellow fruit you know. Before you freak out, know that ethylene is the fully natural plant hormone that induces ripening in most fruits and vegetables.
There is a definite art to this ripening process, and highly valued experts who can assess each shipment of bananas know just how to handle them in the ripening rooms to achieve the goal of delivering just right bananas at retail. This process has to factor in issues like ups and downs in demand and turnover rates at key retail customer outlets, in addition to the condition of the incoming fruit.
I know that at the stores where I shop, I can consistently buy bananas that are close to ripe but not fully, such that I can hope to consume them all before they turn black. We consumers might think we have a balancing act to do when it comes to timing ripening and consumption of the bananas from our counters, but imagine that on a huge scale for the banana distribution chain.
There is one more critical element of the business model: Those ships that come to our ports loaded with bananas certainly cant go back empty. The banana shipping companies are also seriously involved in their back-haul business of bringing back products of interest in the source countries. Having a well-understood, predictable crop helps with running that business efficiently as well.
So for the international banana business to work in a way that provides a relatively low-cost product acceptable to consumers, it needs to be able to function in a reliable and predictable fashion. Figuring out how to do this with a new banana variety would be a huge challenge. How do you grow it efficiently? Can the crop make the trip reliably? How can its ripeness be managed in order to meet both the distribution chain requirements and the needs of consumers for decent counter life? Will all of this work in a way that is compatible with a viable back-haul business?
So while it is easy to think that the banana industry is crazy to depend on one cultivar, Isubmit to you thatit is not without reasonand it implies noirresponsibility.
So does that just mean that we are inevitably going to live out the unintended prophecy of yes, we have no bananas? I think that depends on whether we continue to live in a world where anti-biotechnology groups are able to exercise the control that they currently have over our food system.
Let me explain. Remember that my introduction to bananas was based on excitement about what biotechnology could do for the crop. One of the concepts was to develop bananas that were resistant to that leaf infection disease that can compromise ship-ability. Control of that disease requires something like 40 fungicide sprays a year, so as you can imagine, there would be a huge cost savings if the trees could be made resistant.
The other concept on the table was modifying the banana so that it would stay in that nice yellow, but not yet black, stage longer on the consumers counter. Ill never forget that in the first meeting about that idea, a participant who worked for a UK-based banana importer said in his very British accent: Why would you want to do that? Dont you know that the dustbin is a major consumer of bananas? Obviously, he wasnt attuned to current sensitivity to the need for food waste reduction. I thought it was cool that a banana company was serious about an idea that might reduce food waste, with the hope that it would make consumers more comfortable about buying even more bananas.
Well, these were just theoretical ideas at the time, and they didnt go anywhere because it soon became evident that the anti-GMO forces were quite successful at putting brand-sensitive companies in an untenable spot if they were using GMO crops not just for generic ingredients but for brand-central crops.A dramatic examplewas how fast-food chains like McDonalds moved to avoid biotech potatoes for their signature fries.
It quickly became clear to the banana companies that their brands and their retail store access could be compromised if they pursued GMO options. The irony here is that this would have been the most viable strategy with which to bring genetic diversity into the logical but extreme monoculture of bananas.
Sothe irony is that if the yes, we have no bananas scenario becomes a reality, it will be because we as a global society didnt use a safe, viable, scientifically sound strategy torationally deal with the problem in the banana crop.
Public institution scientists in Australiaand entrepreneurial scientists in Latin America have come up with ways to modify commercially relevant bananas to resist the Fusarium disease. Ideally, there would be the potential to use several approaches, either in the same banana or in different fields; that wouldavoid delay selection for resistance and avoid yet another dependency on a single line. It is likely that the heritage variety Gros Michel could be made commercially viable once again!
If the Fusarium-resistant biotech bananas were introduced, activists would almost certainly attack them as GMO.Would any of the big banana companies have the guts to move forward with the technology in spite of the inevitable brand attacks by NGOs?Would any big food retailers be willing to resist the inevitable pressures not to stock that fruit? That retail blockage strategy is being used today against other new biotech offerings such asnon-browning applesandpotatoesandfast-growing, terrestrially raised salmon.
At one level, this is a question about what will be available for us as consumers. Will we continue to have this highly consumed, reasonably priced, child-friendly, healthy food option? Maybe not. But there is another big question.
One thing I witnessed on those visits to the banana industry back in the 90s was that large communities in Central and South America flourish because of the jobs that this industry creates. We in the rich world will still have lots of other fruit choices if the stores have no bananas, but that flexibility isnt there for the familiesthat have been doing the work to provide us with this staple food option for so many decades.
I would think that most activists are the kind of people who care about the availability of healthy, low-cost fruit options; I doubt that they would want to see the banana-producing communities impoverished. However, if the current paradigm of anti-GMO intimidation of fruit companies and retailers continues, that is where we are headed.
A version of this story originally ran on the GLP on April 16, 2018.
Steve Savage is a plant pathologist and senior contributor to the GLP. His Pop Agriculture podcast is available for listening or subscription on iTunes and Google Podcasts. Follow him on Twitter @grapedoc
Go here to read the rest:
Viewpoint: Biotechnology could save our favorite banana. Will anti-GMO activists stand in the way? - Genetic Literacy Project
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance - November 16th, 2024
- Department of Biotechnology Launches Webinar Series on Biomanufacturing and Biofoundry Initiative - IBG NEWS - November 16th, 2024
- Multimodal scanning of genetic variants with base and prime editing - Nature.com - November 16th, 2024
- NEW INITIATIVE BY THE ITALIAN EMBASSY IN WASHINGTON ON BIOTECHNOLOGY WITH THE MILKEN INSTITUTE AND LEADING RESEARCHERS AND INDUSTRY EXPERTS -... - November 16th, 2024
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at... - November 16th, 2024
- Albany State offers new Master of Science in Integrated Biotechnology program - The Albany Herald - November 16th, 2024
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Benzinga - November 16th, 2024
- iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business - Simply Wall St - November 16th, 2024
- PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks - November 16th, 2024
- We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance - November 16th, 2024
- Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St - November 16th, 2024
- APHIS Announces Final Notice on Additional Exemptions for the Movement of Organisms Modified or Produced Through Genetic Engineering - USDA APHIS - November 16th, 2024
- Adaptimmune nears second approval for TCR-T therapy - European Biotechnology News - November 16th, 2024
- Lundbeck reports 18% revenue growth in third quarter - The Pharma Letter - November 16th, 2024
- BioNTech to boost oncology offering with buy of Biotheus - The Pharma Letter - November 16th, 2024
- Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - November 16th, 2024
- WPI Receives Federal Funding to Address Anticipated Demand for Biology and Biotechnology Professionals and Educators - WPI News - November 3rd, 2024
- Jonathan Dinman to Direct the Institute for Bioscience and Biotechnology Research - College of Computer, Mathematical, and Natural Sciences - November 3rd, 2024
- PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by Analysts - MarketBeat - November 3rd, 2024
- COP16, DSI mechanism for benefit sharing from the use of digital sequence information approved - Renewable Matter - November 3rd, 2024
- Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets - PR Newswire - November 3rd, 2024
- Axonis Therapeutics raises $115 million in Series A financing - The Pharma Letter - November 3rd, 2024
- Regeneron third-quarter 2024 earnings top expectations - The Pharma Letter - November 3rd, 2024
- AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter - November 3rd, 2024
- CEO and Chairman of the Executive Board - European Biotechnology News - November 3rd, 2024
- The transformative potential of biotechnology and AI in healthcare - The Armchair Trader - November 3rd, 2024
- U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Size to Reach USD 16.68 Billion By 2033 - BioSpace - October 6th, 2024
- Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance - October 6th, 2024
- Resolution Therapeutics scores 63.5 million in series B round - The Pharma Letter - October 6th, 2024
- Wiregrass Institute for Biotechnology welcomes local military veteran from Southeast Health as its first computational biologist - AOL - October 6th, 2024
- Generating and characterizing a comprehensive panel of CHO cells glycosylation mutants for advancing glycobiology and biotechnology research -... - October 6th, 2024
- Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum - PR Newswire - October 6th, 2024
- Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter - October 6th, 2024
- Convergence is AIxBio: AI and the Bioeconomy - OODA Loop - October 6th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - ABC News - September 13th, 2024
- Researchers, media engage to educate farmers on biotechnology - University World News - September 13th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - The Associated Press - September 13th, 2024
- Comer Delivers Remarks in Support of Bipartisan BIOSECURE Act - House Committee on Oversight and Reform | - September 13th, 2024
- Announcement of $2 Million for the University of Delaware to Advance Biotechnology - WGMD Radio - September 13th, 2024
- Thailand's Competitiveness Enhanced Through Advanced Biotechnology at Thailand LAB INTERNATIONAL 2024 - BSA bureau - September 13th, 2024
- Biotechnology company Amgen expands global reach with technology innovation center in Hyderabad, India - BioProcess Insider - September 13th, 2024
- Adam's Biotech Scorecard: Can iTeos and GSK solve TIGIT's troubles? - STAT - September 13th, 2024
- Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO) - DirectorsTalk Interviews - September 13th, 2024
- MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Business Wire - September 13th, 2024
- MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks - September 13th, 2024
- Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter - September 13th, 2024
- Chinese biotech firms refute US bill, stressing they have no access to Americans personal data - Global Times - September 13th, 2024
- Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments - TipRanks - September 13th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 13th, 2024
- Time to leverage intellectual property to drive innovation in seed and biotechnology sectors: Experts - The Times of India - May 5th, 2024
- Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week? - InvestorsObserver - March 10th, 2024
- Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver - February 18th, 2024
- Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver - February 18th, 2024
- Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver - February 18th, 2024
- What is Biotechnology? Types and Applications - Iberdrola - January 25th, 2024
- Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver - January 25th, 2024
- Can Sana Biotechnology Inc (SANA) Stock Rise to the Top of Healthcare Sector Monday? - InvestorsObserver - January 25th, 2024
- Should You Buy Sana Biotechnology Inc (SANA) Stock After it Has Fallen 15.41% in a Week? - InvestorsObserver - January 25th, 2024
- Where Does Tscan Therapeutics Inc (TCRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.81% This Week? - InvestorsObserver - January 25th, 2024
- Should Biotechnology Stock Mink Therapeutics Inc (INKT) Be in Your Portfolio Monday? - InvestorsObserver - May 9th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Has Risen 22.18% This Week? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Dermata Therapeutics Inc (DRMA) Be in Your Portfolio Thursday? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Tempest Therapeutics Inc (TPST) Be in Your Portfolio Wednesday? - InvestorsObserver - May 9th, 2023
- Biotechnology - Applications of biotechnology | Britannica - May 1st, 2023
- Where Does BioLine RX Ltd - ADR (BLRX) Stock Fall in the Biotechnology Field After It Is Down -3.67% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Apellis Pharmaceuticals Inc (APLS) Stock Fall in the Biotechnology Field After It Is Higher By 4.17% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Aldeyra Therapeutics Inc (ALDX) Stock Fall in the Biotechnology Field After It Is Lower By -11.45% This Week? - InvestorsObserver - May 1st, 2023
- Is Rain Oncology Inc (RAIN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - April 7th, 2023
- Does Sana Biotechnology Inc (SANA) Have What it Takes to be in Your Portfolio Tuesday? - InvestorsObserver - April 7th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Is Lower By -15.43% This Week? - InvestorsObserver - April 7th, 2023
- Where Does Protagonist Therapeutics Inc (PTGX) Stock Fall in the Biotechnology Field After It Has Risen 3.62% This Week? - InvestorsObserver - April 7th, 2023
- What is Biotechnology? Definition, Types and Applications | TechTarget - March 21st, 2023
- Where Does Novavax Inc (NVAX) Stock Fall in the Biotechnology Field After It Is Lower By -12.99% This Week? - InvestorsObserver - March 21st, 2023
- Should Biotechnology Stock Outlook Therapeutics Inc (OTLK) Be in Your Portfolio Thursday? - InvestorsObserver - March 21st, 2023
- SANA BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com - March 21st, 2023
- Where Does Revance Therapeutics Inc (RVNC) Stock Fall in the Biotechnology Field After It Is Lower By -2.17% This Week? - InvestorsObserver - March 5th, 2023
- Is TG Therapeutics Inc common stock (TGTX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 5th, 2023
- Where Does GT Biopharma Inc (GTBP) Stock Fall in the Biotechnology Field After It Is Down -20.73% This Week? - InvestorsObserver - March 5th, 2023
- Where Does Dyne Therapeutics Inc (DYN) Stock Fall in the Biotechnology Field After It Is Lower By -2.35% This Week? - InvestorsObserver - March 5th, 2023
- Is CytomX Therapeutics Inc (CTMX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - November 17th, 2022